Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

Francesca Maines, Orazio Caffo, Antonello Veccia, Chiara Trentin, Giampaolo Tortora, Enzo Galligioni, Emilio Bria

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Background: Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy. Materials and methods: All published studies reporting monthly OS rates of mCRPC patients receiving third-line NA after having previously received docetaxel and another NA have been analyzed. The treatments were merged into three groups: one NHA followed by another, one NHA followed by CABA, and CABA followed by one NHA. The cumulative monthly OS rates in each group were determined using a weighted-average approach. Results: Thirteen retrospective studies including 1016 patients who received NHA/NHA (469), NHA/CABA (318) or CABA/NHA (229) were evaluated. The 12-month OS rates were 28.5%, 61.3%, and 76.4%, respectively. There were no statistically significant differences in terms of known prognostic factors. Conclusions: Although the retrospective nature of the studies and potential selection biases, our data seem to confirm the potential cumulative survival benefit of using the NAs sequentially after docetaxel. There was no clear superiority of any one of the three strategies, but a sequence that includes CABA seems to suggest a possible OS advantage.

Original languageEnglish
Pages (from-to)498-506
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume96
Issue number3
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Survival Rate
Survival
Retrospective Studies
Selection Bias
cabazitaxel
Cohort Studies

Keywords

  • Abiraterone
  • Cabazitaxel
  • Castration-resistant
  • Enzalutamide
  • Prostate cancer
  • Sequence

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. / Maines, Francesca; Caffo, Orazio; Veccia, Antonello; Trentin, Chiara; Tortora, Giampaolo; Galligioni, Enzo; Bria, Emilio.

In: Critical Reviews in Oncology/Hematology, Vol. 96, No. 3, 01.12.2015, p. 498-506.

Research output: Contribution to journalReview article

Maines, Francesca ; Caffo, Orazio ; Veccia, Antonello ; Trentin, Chiara ; Tortora, Giampaolo ; Galligioni, Enzo ; Bria, Emilio. / Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. In: Critical Reviews in Oncology/Hematology. 2015 ; Vol. 96, No. 3. pp. 498-506.
@article{2c8551ede08d4991a1b0c920cac21bd2,
title = "Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer",
abstract = "Background: Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy. Materials and methods: All published studies reporting monthly OS rates of mCRPC patients receiving third-line NA after having previously received docetaxel and another NA have been analyzed. The treatments were merged into three groups: one NHA followed by another, one NHA followed by CABA, and CABA followed by one NHA. The cumulative monthly OS rates in each group were determined using a weighted-average approach. Results: Thirteen retrospective studies including 1016 patients who received NHA/NHA (469), NHA/CABA (318) or CABA/NHA (229) were evaluated. The 12-month OS rates were 28.5{\%}, 61.3{\%}, and 76.4{\%}, respectively. There were no statistically significant differences in terms of known prognostic factors. Conclusions: Although the retrospective nature of the studies and potential selection biases, our data seem to confirm the potential cumulative survival benefit of using the NAs sequentially after docetaxel. There was no clear superiority of any one of the three strategies, but a sequence that includes CABA seems to suggest a possible OS advantage.",
keywords = "Abiraterone, Cabazitaxel, Castration-resistant, Enzalutamide, Prostate cancer, Sequence",
author = "Francesca Maines and Orazio Caffo and Antonello Veccia and Chiara Trentin and Giampaolo Tortora and Enzo Galligioni and Emilio Bria",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.critrevonc.2015.07.013",
language = "English",
volume = "96",
pages = "498--506",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

AU - Maines, Francesca

AU - Caffo, Orazio

AU - Veccia, Antonello

AU - Trentin, Chiara

AU - Tortora, Giampaolo

AU - Galligioni, Enzo

AU - Bria, Emilio

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy. Materials and methods: All published studies reporting monthly OS rates of mCRPC patients receiving third-line NA after having previously received docetaxel and another NA have been analyzed. The treatments were merged into three groups: one NHA followed by another, one NHA followed by CABA, and CABA followed by one NHA. The cumulative monthly OS rates in each group were determined using a weighted-average approach. Results: Thirteen retrospective studies including 1016 patients who received NHA/NHA (469), NHA/CABA (318) or CABA/NHA (229) were evaluated. The 12-month OS rates were 28.5%, 61.3%, and 76.4%, respectively. There were no statistically significant differences in terms of known prognostic factors. Conclusions: Although the retrospective nature of the studies and potential selection biases, our data seem to confirm the potential cumulative survival benefit of using the NAs sequentially after docetaxel. There was no clear superiority of any one of the three strategies, but a sequence that includes CABA seems to suggest a possible OS advantage.

AB - Background: Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy. Materials and methods: All published studies reporting monthly OS rates of mCRPC patients receiving third-line NA after having previously received docetaxel and another NA have been analyzed. The treatments were merged into three groups: one NHA followed by another, one NHA followed by CABA, and CABA followed by one NHA. The cumulative monthly OS rates in each group were determined using a weighted-average approach. Results: Thirteen retrospective studies including 1016 patients who received NHA/NHA (469), NHA/CABA (318) or CABA/NHA (229) were evaluated. The 12-month OS rates were 28.5%, 61.3%, and 76.4%, respectively. There were no statistically significant differences in terms of known prognostic factors. Conclusions: Although the retrospective nature of the studies and potential selection biases, our data seem to confirm the potential cumulative survival benefit of using the NAs sequentially after docetaxel. There was no clear superiority of any one of the three strategies, but a sequence that includes CABA seems to suggest a possible OS advantage.

KW - Abiraterone

KW - Cabazitaxel

KW - Castration-resistant

KW - Enzalutamide

KW - Prostate cancer

KW - Sequence

UR - http://www.scopus.com/inward/record.url?scp=84983190595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983190595&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.07.013

DO - 10.1016/j.critrevonc.2015.07.013

M3 - Review article

VL - 96

SP - 498

EP - 506

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -